ArticleScientific reports2026
Adaptation and validation of an influenza a subtyping panel for detection of H1pdm09, H3 and H5 on a high-throughput RT-qPCR system.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Facing the emergence of highly pathogenic avian influenza virus (HPAIV) H5N1 clade 2.3.4.4b in birds and its circulation in dairy cattle, rapid and reliable assays to detect HPAIV infection in humans are needed in diagnostic laboratories worldwide. We adapted and evaluated the performance of a molecular influenza A subtyping assay for the detection of A(H1N1)pdm09, A(H3N2), A(H5) and a pan-influenza A target on a high-throughput, fully automated platform. Previously published target primers and probes (Panning et al., Terrier et al., and the World Health Organization) were modified for target inclusivity/exclusivity, and adapted to compatibility with the Roche cobas5800/6800/8800 system as multiplex reaction. To evaluate the analytical performance of the new subtyping assay external quality assessment (EQA) samples were used as standards and quantified by digital-PCR. Limits of detection determined by 95% probit analysis were 754.0 digital copies (dcp)/ml for A(H1N1)pdm09, 148.0 dcp/ml for A(H3N2), 156 dcp/ml for A(H5) and 45.2 dcp/ml for the influenza A pan-target. Linearity was assessed for each subtyping target over at least four log-steps (r2: 0.9969–0.9998). The assay showed 100% agreement with EQA samples, eluates from the Friedrich Loeffler Institut (Germany) tested positive for different influenza A subtypes, and CE-IVD manual tests using 132 clinical samples. No false positives were detected in the exclusivity set. Our new subtyping assay is fully automated, easily scalable and can be used in surveillance and routine clinical settings enabling the detection of HPAIV infections in humans and may contribute to limit potential transmission chains at an early stage. Words: 250/250.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.